CN112691077B - Processing method of glucose injection - Google Patents
Processing method of glucose injection Download PDFInfo
- Publication number
- CN112691077B CN112691077B CN202011604061.0A CN202011604061A CN112691077B CN 112691077 B CN112691077 B CN 112691077B CN 202011604061 A CN202011604061 A CN 202011604061A CN 112691077 B CN112691077 B CN 112691077B
- Authority
- CN
- China
- Prior art keywords
- aqueous solution
- pipe body
- plate
- tube
- sodium alginate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 55
- 229940093181 glucose injection Drugs 0.000 title claims abstract description 23
- 238000003672 processing method Methods 0.000 title claims abstract description 10
- 239000007864 aqueous solution Substances 0.000 claims abstract description 128
- 238000002156 mixing Methods 0.000 claims abstract description 73
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 48
- 108010022355 Fibroins Proteins 0.000 claims abstract description 48
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 48
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 48
- 239000000661 sodium alginate Substances 0.000 claims abstract description 48
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 41
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 41
- 239000008103 glucose Substances 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 27
- 239000011259 mixed solution Substances 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 11
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims abstract description 9
- 229920001983 poloxamer Polymers 0.000 claims abstract description 9
- 229960000502 poloxamer Drugs 0.000 claims abstract description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 8
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 4
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 4
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 4
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000010008 shearing Methods 0.000 claims abstract description 4
- 230000001954 sterilising effect Effects 0.000 claims abstract description 4
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 4
- 229940046009 vitamin E Drugs 0.000 claims abstract description 4
- 239000011709 vitamin E Substances 0.000 claims abstract description 4
- 238000005192 partition Methods 0.000 claims description 54
- 229940079593 drug Drugs 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 12
- 238000006386 neutralization reaction Methods 0.000 claims description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 235000014375 Curcuma Nutrition 0.000 claims description 3
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 3
- 238000005374 membrane filtration Methods 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 229940060184 oil ingredients Drugs 0.000 claims description 3
- 235000019198 oils Nutrition 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 2
- 244000164480 Curcuma aromatica Species 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- -1 polyethylene Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 239000012528 membrane Substances 0.000 abstract description 2
- 240000009138 Curcuma zedoaria Species 0.000 abstract 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 239000010681 turmeric oil Substances 0.000 abstract 1
- 238000002604 ultrasonography Methods 0.000 abstract 1
- 235000019509 white turmeric Nutrition 0.000 abstract 1
- 235000001727 glucose Nutrition 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 230000003472 neutralizing effect Effects 0.000 description 6
- 229940090044 injection Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000407170 Curcuma Species 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
- B01F25/60—Pump mixers, i.e. mixing within a pump
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
技术领域technical field
本发明属于药物制剂技术领域,尤其是涉及一种葡萄糖注射液的加工方法。The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a processing method of glucose injection.
背景技术Background technique
脂溶性药物药理活性显著,有效成分容易发生氧化变质影响药性,而且在人体内环境中溶解度低,难以达到药物的有效浓度。因此,临床常用增溶剂提高脂溶性药物的稳定性和溶解度,同时实现靶向,提高药物的生物利用度,降低毒副作用。Lipid-soluble drugs have significant pharmacological activity, the active ingredients are prone to oxidative deterioration and affect the drug properties, and the solubility in the human body environment is low, so it is difficult to achieve the effective concentration of the drug. Therefore, solubilizers are commonly used in clinical practice to improve the stability and solubility of fat-soluble drugs, and at the same time achieve targeting, improve drug bioavailability, and reduce toxic side effects.
当双层膜的脂质体作为水溶性药物传递系统时,尚存在热力学不稳定问题,但其应用到脂溶性药物包括时,呈单层膜,稳定性变得极差。泊洛沙姆生物相容性好,但稳定性差,而在临床脂溶性药物注射液应用中以吐温-80为主,但其存在较高的溶血风险,限制了药物的使用范围及药物浓度。目前市场缺少高安全、高稳定性、高载药量的注射液制剂,因此寻找一种更安全、稳定、高载药量的脂溶性药物注射液制剂制备方法显得尤为重要。When the bilayer membrane liposome is used as a water-soluble drug delivery system, there is still the problem of thermodynamic instability, but when it is applied to lipid-soluble drugs, it is a single-layer membrane, and the stability becomes extremely poor. Poloxamer has good biocompatibility but poor stability, and Tween-80 is the main application in clinical lipid-soluble drug injection, but it has a high risk of hemolysis, which limits the scope of drug use and drug concentration . At present, there is a lack of injection preparations with high safety, high stability and high drug loading in the market. Therefore, it is particularly important to find a safer, more stable and high drug loading preparation method for lipid-soluble drug injection preparations.
发明内容SUMMARY OF THE INVENTION
本发明为了克服现有技术的不足,提供一种葡萄糖注射液的加工方法。In order to overcome the deficiencies of the prior art, the present invention provides a processing method of glucose injection.
为了实现上述目的,本发明采用以下技术方案:一种葡萄糖注射液的加工方法,葡萄糖注射液包括脂溶性药物和囊材,所述囊材按重量份:海藻酸钠15~45份、泊洛沙姆2.5~9份、丝素蛋白1.5~5份、聚乙烯醇0.5~3份、聚乙二醇0.2~3份;所述脂溶性药物为莪术油、维生素E或辅酶Q10,其重量份为15~45份;还包括占总体积5%的质量的葡萄糖,包括以下步骤:In order to achieve the above purpose, the present invention adopts the following technical scheme: a method for processing glucose injection, the glucose injection comprises a fat-soluble drug and a capsule material, and the capsule material is in parts by weight: 15-45 parts of sodium alginate, polox 2.5-9 parts of sham, 1.5-5 parts of silk fibroin, 0.5-3 parts of polyvinyl alcohol, and 0.2-3 parts of polyethylene glycol; the fat-soluble drug is curcuma oil, vitamin E or coenzyme Q10, and its weight parts It is 15 to 45 parts; it also includes 5% of the mass of the total volume of glucose, including the following steps:
步骤a:配制海藻酸钠水溶液、丝素蛋白水溶液和聚乙烯醇水溶液;步骤b:通过混合装置对海藻酸钠水溶液、丝素蛋白水溶液和聚乙烯醇水溶液及葡萄糖进行混合,得到混合液A;Step a: preparing an aqueous solution of sodium alginate, an aqueous solution of silk fibroin and an aqueous solution of polyvinyl alcohol; step b: mixing the aqueous solution of sodium alginate, the aqueous solution of silk fibroin, the aqueous solution of polyvinyl alcohol and glucose through a mixing device to obtain a mixed solution A;
步骤c:向混合液A中加入泊洛沙姆、聚乙二醇,均匀混合后,最后采用逐滴滴加的方式滴加脂溶性药物,得到混合液B;Step c: adding poloxamer and polyethylene glycol to the mixed solution A, after uniform mixing, and finally adding the fat-soluble drug dropwise to obtain the mixed solution B;
步骤d:采用超声、剪切进行处理,450nm膜过滤、湿热灭菌即得葡萄糖注射液;Step d: Ultrasonic and shearing are used for processing, 450nm membrane filtration, and moist heat sterilization to obtain glucose injection;
其中步骤b中的混合装置包括中和混合泵、与所述中和混合泵配合的混合套管及连接所述中和混合泵与第一进料管的第三连接管,所述混合套管设有四层,从外到内依次供海藻酸钠水溶液、丝素蛋白水溶液、聚乙烯醇水溶液及葡萄糖;所述混合套管包括第一管体、设于第一管体内的第二管体、设于第二管体内的第三管体、设于第三管体内的第四管体、设于第二管体上的多组第一孔组、设于第三管体上的多组第二孔组、设于第四管体上的多组第三孔组、设于首端第一孔组处的第一分流组件、设于首端第二孔组处的第二分流组件、设于首端第三孔组处的第三分流组件、设于第一管体和第二管体之间的第一隔板及第二隔板、设于第二管体和第三管体之间的第三隔板、第四隔板、第五隔板及第六隔板、设于第三管体和第四管体之间的第七隔板、第八隔板、第九隔板及第十隔板,所述相邻两组第一孔组对称设置,所述第一孔组由等距环形分布设于第二管体上的多个第一弧形孔组成;通过第一隔板设置,使位于第一管体和第二管体之间的海藻酸钠水溶液通过首端的第一孔组进入第二管体和第三管体之间,与第二管体和第三管体内的丝素蛋白水溶液混合,通过首端的第一分流组件使海藻酸钠水溶液和丝素蛋白水溶液快速的混合,通过第三隔板使二者混合后通过首端的第二孔组进入第三管体和第四管体之间,与第三管体和第四管体内的聚乙烯醇水溶液混合,通过首端的第二分流组件使海藻酸钠水溶液和丝素蛋白水溶液及聚乙烯醇水溶液三者快速混合,通过第七隔板使三者混合后通过首端的第三孔组进入第四管体内,与第四管体内的葡萄糖混合,通过第三分流组件使海藻酸钠水溶液、丝素蛋白水溶液和聚乙烯醇水溶液及葡萄糖四者快速混合,四者混合后通过首端第三孔组相邻的第三孔组重新回到第四管体和第三管体之间,依次通过首端第二孔组相邻的第二孔组和首端第一孔组相邻的第一孔组,依次进入第三管体和第二管体之间及第一管体和第二管体之间,所述第一孔组、第二孔组及第三孔组设有多个,通过第一隔板至第十隔板使海藻酸钠水溶液、丝素蛋白水溶液和聚乙烯醇水溶液及葡萄糖四个混合,混合后不断的往返第一管体和第二管体之间、第二管体和第三管体之间、第三管体和第四管体之间、第四管体内,从而延长了四者混合的流经长度,使四者混合中和的效果更好,再通过混合泵进一步的混合。Wherein the mixing device in step b includes a neutralizing and mixing pump, a mixing sleeve matched with the neutralizing and mixing pump, and a third connecting pipe connecting the neutralizing and mixing pump and the first feeding pipe, and the mixing sleeve There are four layers, and the sodium alginate aqueous solution, the silk fibroin aqueous solution, the polyvinyl alcohol aqueous solution and the glucose are sequentially supplied from the outside to the inside; the mixing sleeve includes a first tube body and a second tube body arranged in the first tube body. , The third tube body set in the second tube body, the fourth tube body set in the third tube body, the multiple groups of the first hole groups set on the second tube body, the multiple sets of the first hole set set on the third tube body a second hole group, a plurality of groups of third hole groups arranged on the fourth pipe body, a first shunt assembly arranged at the first hole group at the head end, a second flow shunt assembly arranged at the second hole group at the head end, a third splitter assembly located at the third hole group at the head end, a first baffle and a second baffle between the first pipe body and the second pipe body, and the second pipe body and the third pipe body The third partition, the fourth partition, the fifth partition and the sixth partition between the third and fourth tubes, the seventh partition, the eighth partition and the ninth partition plate and the tenth partition plate, the adjacent two groups of first hole groups are symmetrically arranged, and the first hole groups are composed of a plurality of first arc holes arranged in an equidistant annular distribution on the second pipe body; A partition plate is provided, so that the sodium alginate aqueous solution located between the first pipe body and the second pipe body enters between the second pipe body and the third pipe body through the first hole group at the head end, and is connected with the second pipe body and the third pipe body. The silk fibroin aqueous solution in the three tubes is mixed, and the sodium alginate aqueous solution and the silk fibroin aqueous solution are quickly mixed through the first shunt component at the head end, and the two are mixed through the third separator, and then enter the first end through the second hole group at the head end. Between the third pipe body and the fourth pipe body, it is mixed with the polyvinyl alcohol aqueous solution in the third pipe body and the fourth pipe body. The three are quickly mixed, and the three are mixed through the seventh separator and then enter the fourth tube through the third hole group at the head end, mixed with the glucose in the fourth tube, and the sodium alginate aqueous solution, silk fibroin The protein aqueous solution, the polyvinyl alcohol aqueous solution and the glucose are rapidly mixed, and after the four are mixed, they return to between the fourth tube body and the third tube body through the third hole group adjacent to the third hole group at the first end, and pass through the first tube body in turn. The second hole group adjacent to the second hole group at the end and the first hole group adjacent to the first hole group at the head end enter between the third pipe body and the second pipe body and between the first pipe body and the second pipe body in turn. In between, the first hole group, the second hole group and the third hole group are provided with a plurality of, and the sodium alginate aqueous solution, the silk fibroin aqueous solution, the polyvinyl alcohol aqueous solution and the The four glucoses are mixed, and after mixing, they go back and forth between the first tube body and the second tube body, between the second tube body and the third tube body, between the third tube body and the fourth tube body, and in the fourth tube body. , so as to prolong the flow length of the mixing of the four, so that the effect of the mixing and neutralization of the four is better, and then the mixing pump is used for further mixing.
优选的,所述混合套管还包括等距环形分布贯穿设于第二隔板上且一端固定设于第一隔板上的多个第一杆体、等距环形分布贯穿设于第四隔板和第五隔板及第六隔板上且一端固定设于第三隔板上的多个第二杆体、等距环形分布贯穿设于第八隔板和第九隔板及第十隔板上且一端固定设于第七隔板上的多个第三杆体;通过第一杆体设置使进入第一管体和第二管体之间的海藻酸钠水溶液、丝素蛋白水溶液和聚乙烯醇水溶液及葡萄糖进行分流,起到很好的混合效果,通过第二杆体设置使进入第二管体和第三管体之间的海藻酸钠水溶液、丝素蛋白水溶液和聚乙烯醇水溶液及葡萄糖进行分流,起到很好的混合效果,通过第三杆体设置使进入第四管体和第三管体之间的海藻酸钠水溶液、丝素蛋白水溶液和聚乙烯醇水溶液及葡萄糖进行分流,起到很好的混合效果,即海藻酸钠水溶液、丝素蛋白水溶液和聚乙烯醇水溶液及葡萄糖流动过程中经过多次的分流混合,能够大大提高其混合效率及效果,混合过程中不需要停顿。Preferably, the mixing sleeve further comprises a plurality of first rod bodies which are arranged in an equidistant annular distribution through the second partition and one end is fixedly arranged on the first partition, and are arranged in an equidistant annular distribution through the fourth partition. and a plurality of second rod bodies, one end of which is fixed on the third partition board, and the fifth partition board and the sixth partition board, and the equidistant annular distribution runs through the eighth partition board, the ninth partition board and the tenth partition board. And one end is fixed on a plurality of third rod bodies on the seventh partition board; the sodium alginate aqueous solution, silk fibroin aqueous solution and polyvinyl alcohol aqueous solution entering between the first tube body and the second tube body are set by the first rod body and glucose for shunting, which has a good mixing effect. The sodium alginate aqueous solution, silk fibroin aqueous solution, polyvinyl alcohol aqueous solution and glucose entering between the second tube body and the third tube body are separated by the setting of the second rod body. , play a very good mixing effect, through the setting of the third rod body, the sodium alginate aqueous solution, silk fibroin aqueous solution, polyvinyl alcohol aqueous solution and glucose entering between the fourth tube body and the third tube body are shunted, which plays a very important role in shunting. A good mixing effect, that is, the sodium alginate aqueous solution, the silk fibroin aqueous solution, the polyvinyl alcohol aqueous solution and the glucose flow through multiple shunt mixing can greatly improve the mixing efficiency and effect, and there is no need to pause during the mixing process.
优选的,海藻酸钠水溶液质量分数为0.5%~2.0%、丝素蛋白水溶液质量分数为0.5%~2%、聚乙烯醇水溶液质量分数为0.5%~2%。Preferably, the mass fraction of the sodium alginate aqueous solution is 0.5%-2.0%, the mass fraction of the silk fibroin aqueous solution is 0.5%-2%, and the mass fraction of the polyvinyl alcohol aqueous solution is 0.5%-2%.
优选的,所述第一分流组件包括第一锥形板、设于第一锥形板内的第一腔体、等距环形分布设于第一锥形板上的多个第一出水管、贯穿设于第一锥形板上的多个第二出水管、固定设于第二管体内壁上的第一固定环、等距环形分布固定设于第一固定环上的多个分流板、设于分流板中间处的第一通孔;海藻酸钠水溶液通过多个第一弧形孔进入第一锥形板内的第一腔体,通过第一腔体上的多个第一出水管排出就进入第二管体和第三管体之间,第二管体和第三管体之间的丝素蛋白水溶液从多个第二出水管排出,通过第一锥形板设置使由内道外从第一出水管排出的海藻酸钠水溶液流速依次增加,使由内道外从第二出水管排出的丝素蛋白水溶液依次增加,在通过第一固定环设置从而使该处的二者混合后形成涡流,提高二者混合效果,再通过多个分流板使二者向其两侧流动,一部分通过其上的第一通孔流动,与经过相邻分流板分流的二者混合相碰触混合,第一出水管与第二出水管交错设置能够大大提高了二者的混合效果。Preferably, the first flow distribution component includes a first conical plate, a first cavity provided in the first conical plate, a plurality of first water outlet pipes arranged in an equidistant annular distribution on the first conical plate, a plurality of second water outlet pipes running through the first conical plate, a first fixing ring fixed on the inner wall of the second pipe, a plurality of distribution plates fixed on the first fixing ring in an equidistant annular distribution, A first through hole located in the middle of the distribution plate; the sodium alginate aqueous solution enters the first cavity in the first conical plate through a plurality of first arc holes, and passes through a plurality of first water outlet pipes on the first cavity The discharge enters between the second pipe body and the third pipe body, and the silk fibroin aqueous solution between the second pipe body and the third pipe body is discharged from a plurality of second water outlet pipes, and the first conical plate is arranged so that the inner The flow rate of the sodium alginate aqueous solution discharged from the first water outlet pipe outside the channel increases in turn, so that the silk fibroin aqueous solution discharged from the second water outlet pipe from the outside of the inner channel increases in turn. A vortex is formed to improve the mixing effect of the two, and then the two flow to both sides through a plurality of diverting plates, a part of which flows through the first through hole on it, and is mixed with the two mixed through the adjacent diverting plates. The staggered arrangement of the first water outlet pipe and the second water outlet pipe can greatly improve the mixing effect of the two.
优选的,所述第三分流组件包括设于第四管体轴心处的转轴、固定套设于转轴上的第一轴套、转动套设于转轴上且固定设于第四管体内壁上的第二轴套、固定设于第四管体内壁上的第二固定环、设于第二固定环中间处的第二通孔、固定设于转轴上的旋涡状聚流板、固定套设于转轴上的圆板、等距设于旋涡状聚流板上的多个斜板、位于斜板一端设于旋涡状聚流板上的第三通孔、位于斜板另一端设于旋涡状聚流板上的第四通孔;通过中和混合泵驱动转轴转动,使转轴上的旋涡状聚流板转动,第四管体内的葡萄糖从第四管体和圆板之间通过,与通过第三孔组进入的海藻酸钠水溶液、丝素蛋白水溶液和聚乙烯醇水溶液三者混合料,旋涡状聚流板转动过程中使四者混合料向其中间流动,从固定环中间处的第二通孔向第一轴套方向流动,使四者聚集混合,通过其上的多个斜板设置能够使四者改变其流动的方向,整体起到很好的混合效果,通过第三通孔和第四通孔能够减少旋涡状聚流板转动过程中受到的阻力,还能够使四者混合料流经第三通孔和第四通孔,提高其第三通孔和第四通孔处的流动速度,提高该处的混合效果,通过第一轴套和第二轴套设置能够使转轴转动过程中更为平稳,降低转动过程中的晃动,提高转轴的使用寿命,四者通过旋涡状聚流板聚集后从第二通孔向第一轴套方向流动,经过第一轴套再对四者进行分流,即先对四者进行聚流冲击混合,再对四者进行分流,大大提高了对四者的混合效果和效率。Preferably, the third flow distribution assembly includes a rotating shaft disposed at the axis of the fourth pipe body, a first sleeve fixedly sleeved on the rotating shaft, rotatably sleeved on the rotating shaft and fixedly disposed on the inner wall of the fourth pipe The second shaft sleeve, the second fixed ring fixed on the inner wall of the fourth tube, the second through hole set in the middle of the second fixed ring, the vortex-shaped concentrator fixed on the rotating shaft, the fixed sleeve A circular plate on the rotating shaft, a plurality of inclined plates arranged on the vortex-shaped collecting plate at equal intervals, a third through hole located on one end of the inclined plate on the vortex-shaped collecting plate, and a third through hole located on the other end of the inclined plate on the vortex-shaped collecting plate. The fourth through hole on the converging plate; the rotating shaft is driven to rotate by the neutralization mixing pump, so that the vortex converging plate on the rotating shaft rotates, and the glucose in the fourth tube passes between the fourth tube and the circular plate, and passes through the The three mixtures of sodium alginate aqueous solution, silk fibroin aqueous solution and polyvinyl alcohol aqueous solution entered into the third hole group, the four mixtures flow to the middle of the vortex concentrator during the rotation process, from the third hole in the middle of the fixed ring. The two through holes flow in the direction of the first bushing, so that the four can be gathered and mixed, and the four can change the direction of their flow through the arrangement of a plurality of inclined plates on it, and the overall mixing effect is very good. and the fourth through hole can reduce the resistance during the rotation of the vortex collecting plate, and can also make the four mixed materials flow through the third through hole and the fourth through hole, and improve the position of the third through hole and the fourth through hole. The flow speed of the rotating shaft can be increased to improve the mixing effect at the place. The arrangement of the first bushing and the second bushing can make the rotation process of the rotating shaft more stable, reduce the shaking during the rotation process, and improve the service life of the rotating shaft. After the concentrators gather, they flow from the second through hole to the direction of the first bushing, and then pass through the first bushing and then divide the flow of the four, that is, the four are first subjected to converging and impact mixing, and then the four are divided, which greatly improves the The mixing effect and efficiency of the four are obtained.
优选的,所述第一轴套包括套体、固定设于套体一端的第一锥形体、等距环形分布固定设于第一锥形体上的固定板、转动设于固定板上的从动轴、固定套设于从动轴上的第二锥形体、固定套设于从动轴上的空心管、等距环形分布设于空心管上的多个第五通孔及第六通孔、固定设于空心管一端的锥形环;转轴转动过程中带动第一轴套转动,使套体转动,使第一锥形体转动,使第一锥形体上的多个固定板以转轴为轴心进行公转,通过第一锥形体设置能够使流经该处的四者混合料向外流动,流动过程中一部分直接进入空心管内,一部分通过第五通孔进入空心管内,使与直接进入空心管内的四者混合料相冲击混合,空心管内的混合料通过第六通孔排出,并流经第二锥形体,再次对其进行向外分流,通过从动轴转动设置在固定板上,从而使空心管可以转动,使位于其内的四者混合料更容易混合,空心管内的混合料一部分会从其它第五通孔流出,能够降低空心管公转过程中受到的阻力,通过空心管公转能够使四组流经该处时混合的更为全面。Preferably, the first shaft sleeve comprises a sleeve body, a first conical body fixed on one end of the sleeve body, a fixed plate fixed on the first conical body in an equidistant annular distribution, and a driven plate rotatably disposed on the fixed plate a shaft, a second conical body fixedly sleeved on the driven shaft, a hollow tube fixedly sleeved on the driven shaft, a plurality of fifth through holes and sixth through holes arranged in an equidistant annular distribution on the hollow tube, A conical ring is fixed on one end of the hollow tube; during the rotation of the rotating shaft, the first shaft sleeve is driven to rotate, the sleeve body rotates, and the first conical body rotates, so that the plurality of fixed plates on the first conical body take the rotating shaft as the axis During the revolution, the four-component mixture flowing through the place can be made to flow outward through the setting of the first conical body. During the flow process, a part directly enters the hollow tube, and a part enters the hollow tube through the fifth through hole, so as to make the The mixture of the four is impacted and mixed, and the mixture in the hollow tube is discharged through the sixth through hole, and flows through the second cone, and is divided outward again. The tube can be rotated to make it easier to mix the four mixtures in it, and a part of the mixture in the hollow tube will flow out from the other fifth through holes, which can reduce the resistance during the revolution of the hollow tube. The group is more fully mixed as it flows through it.
综上所述,脂溶性药物亚微囊葡萄糖注射液为稳定体系,离心后溶液澄清透明,无分层无悬浮液,亚微囊体系包裹均匀,亚微囊粒径大小均一;添加了亚微囊材泊洛沙姆,安全无毒,可有效改善微囊的均一度、稳定性;解决了现有脂溶性药物亚微囊安全低、稳定性差、载药量低的技术问题,通过混合装置制备的萄糖注射液各原料之间混合的更加均匀,使的与血液相容性良好,更好的解决了上述更安全、稳定、高载药量的脂溶性葡萄糖注射液问题。To sum up, the lipid-soluble drug submicrocapsule glucose injection is a stable system, the solution is clear and transparent after centrifugation, without delamination or suspension, the submicrocapsule system is evenly packaged, and the submicrocapsule particle size is uniform; The capsule material poloxamer is safe and non-toxic, and can effectively improve the uniformity and stability of the microcapsules; it solves the technical problems of low safety, poor stability and low drug loading of the existing fat-soluble drug submicrocapsules. The raw materials of the prepared glucose injection are more evenly mixed, so that the compatibility with blood is good, and the above-mentioned problem of the above-mentioned safer, more stable and high drug-loading fat-soluble glucose injection is better solved.
附图说明Description of drawings
图1为本发明的剖视图。FIG. 1 is a cross-sectional view of the present invention.
图2为图1中的A处放大图。FIG. 2 is an enlarged view of part A in FIG. 1 .
图3为图1中的B处放大图。FIG. 3 is an enlarged view of B in FIG. 1 .
图4为图1中的B-B线的部分剖视图。FIG. 4 is a partial cross-sectional view taken along the line B-B in FIG. 1 .
图5为图1中的C-C线的部分剖视图。FIG. 5 is a partial cross-sectional view taken along line C-C in FIG. 1 .
图6为图1中的D-D线的部分剖视图。FIG. 6 is a partial cross-sectional view taken along the line D-D in FIG. 1 .
图7为图1中的E-E线的剖视图。FIG. 7 is a cross-sectional view taken along the line E-E in FIG. 1 .
图8为图1中的F-F线的剖视图。FIG. 8 is a cross-sectional view taken along the line F-F in FIG. 1 .
图9为图8中的C处放大图。FIG. 9 is an enlarged view of C in FIG. 8 .
图10为第二管体的结构示意图。FIG. 10 is a schematic structural diagram of the second pipe body.
具体实施方式Detailed ways
如图1-10所示,一种葡萄糖注射液的加工方法,葡萄糖注射液包括脂溶性药物和囊材,所述囊材按重量份:海藻酸钠15~45份、泊洛沙姆2.5~9份、丝素蛋白1.5~5份、聚乙烯醇0.5~3份、聚乙二醇0.2~3份;所述脂溶性药物为莪术油、维生素E或辅酶Q10,其重量份为15~45份;还包括占总体积5%的质量的葡萄糖,包括以下步骤:As shown in Figure 1-10, a method for processing a glucose injection, the glucose injection includes a fat-soluble drug and a capsule material, and the capsule material is by weight: 15-45 parts of sodium alginate, 2.5-45 parts of poloxamer 9 parts, 1.5 to 5 parts of silk fibroin, 0.5 to 3 parts of polyvinyl alcohol, and 0.2 to 3 parts of polyethylene glycol; the fat-soluble drug is curcuma oil, vitamin E or coenzyme Q10, and its parts by weight are 15 to 45 parts by weight servings; also including 5% of the mass of the total volume of glucose, including the following steps:
步骤a:配制海藻酸钠水溶液、丝素蛋白水溶液和聚乙烯醇水溶液;步骤b:通过混合装置对海藻酸钠水溶液、丝素蛋白水溶液和聚乙烯醇水溶液及葡萄糖进行混合,得到混合液A;Step a: preparing an aqueous solution of sodium alginate, an aqueous solution of silk fibroin and an aqueous solution of polyvinyl alcohol; step b: mixing the aqueous solution of sodium alginate, the aqueous solution of silk fibroin, the aqueous solution of polyvinyl alcohol and glucose through a mixing device to obtain a mixed solution A;
步骤c:向混合液A中加入泊洛沙姆、聚乙二醇,均匀混合后,最后采用逐滴滴加的方式滴加脂溶性药物,得到混合液B;Step c: adding poloxamer and polyethylene glycol to the mixed solution A, after uniform mixing, and finally adding the fat-soluble drug dropwise to obtain the mixed solution B;
步骤d:采用超声、剪切进行处理,450nm膜过滤、湿热灭菌即得葡萄糖注射液;Step d: Ultrasonic and shearing are used for processing, 450nm membrane filtration, and moist heat sterilization to obtain glucose injection;
其中步骤b中的混合装置包括中和混合泵11、与所述中和混合泵配合的混合套管12及连接所述中和混合泵与第一进料管的第三连接管13,所述混合套管设有四层,从外到内依次供海藻酸钠水溶液、丝素蛋白水溶液、聚乙烯醇水溶液及葡萄糖;所述混合套管12包括第一管体121、设于第一管体内的第二管体122、设于第二管体内的第三管体123、设于第三管体内的第四管体124、设于第二管体上的多组第一孔组125、设于第三管体上的多组第二孔组126、设于第四管体上的多组第三孔组127、设于首端第一孔组处的第一分流组件128、设于首端第二孔组处的第二分流组件129、设于首端第三孔组处的第三分流组件130、设于第一管体和第二管体之间的第一隔板131及第二隔板132、设于第二管体和第三管体之间的第三隔板133、第四隔板134、第五隔板135及第六隔板136、设于第三管体和第四管体之间的第七隔板137、第八隔板138、第九隔板139及第十隔板140,所述相邻两组第一孔组对称设置,所述第一孔组由等距环形分布设于第二管体上的多个第一弧形孔141组成;通过第一隔板设置,使位于第一管体和第二管体之间的海藻酸钠水溶液通过首端的第一孔组进入第二管体和第三管体之间,与第二管体和第三管体内的丝素蛋白水溶液混合,通过首端的第一分流组件使海藻酸钠水溶液和丝素蛋白水溶液快速的混合,通过第三隔板使二者混合后通过首端的第二孔组进入第三管体和第四管体之间,与第三管体和第四管体内的聚乙烯醇水溶液混合,通过首端的第二分流组件使海藻酸钠水溶液和丝素蛋白水溶液及聚乙烯醇水溶液三者快速混合,通过第七隔板使三者混合后通过首端的第三孔组进入第四管体内,与第四管体内的葡萄糖混合,通过第三分流组件使海藻酸钠水溶液、丝素蛋白水溶液和聚乙烯醇水溶液及葡萄糖四者快速混合,四者混合后通过首端第三孔组相邻的第三孔组重新回到第四管体和第三管体之间,依次通过首端第二孔组相邻的第二孔组和首端第一孔组相邻的第一孔组,依次进入第三管体和第二管体之间及第一管体和第二管体之间,所述第一孔组、第二孔组及第三孔组设有多个,通过第一隔板至第十隔板使海藻酸钠水溶液、丝素蛋白水溶液和聚乙烯醇水溶液及葡萄糖四个混合,混合后不断的往返第一管体和第二管体之间、第二管体和第三管体之间、第三管体和第四管体之间、第四管体内,从而延长了四者混合的流经长度,使四者混合中和的效果更好,再通过混合泵进一步的混合。The mixing device in step b includes a neutralizing and mixing pump 11, a mixing sleeve 12 matched with the neutralizing and mixing pump, and a third connecting pipe 13 connecting the neutralizing and mixing pump and the first feeding pipe. The mixing sleeve is provided with four layers, and sequentially supplies sodium alginate aqueous solution, silk fibroin aqueous solution, polyvinyl alcohol aqueous solution and glucose from the outside to the inside; the mixing sleeve 12 includes a
如图1、7所示,所述混合套管12还包括等距环形分布贯穿设于第二隔板上且一端固定设于第一隔板上的多个第一杆体142、等距环形分布贯穿设于第四隔板和第五隔板及第六隔板上且一端固定设于第三隔板上的多个第二杆体143、等距环形分布贯穿设于第八隔板和第九隔板及第十隔板上且一端固定设于第七隔板上的多个第三杆体144;通过第一杆体设置使进入第一管体和第二管体之间的海藻酸钠水溶液、丝素蛋白水溶液和聚乙烯醇水溶液及葡萄糖进行分流,起到很好的混合效果,通过第二杆体设置使进入第二管体和第三管体之间的海藻酸钠水溶液、丝素蛋白水溶液和聚乙烯醇水溶液及葡萄糖进行分流,起到很好的混合效果,通过第三杆体设置使进入第四管体和第三管体之间的海藻酸钠水溶液、丝素蛋白水溶液和聚乙烯醇水溶液及葡萄糖进行分流,起到很好的混合效果,即海藻酸钠水溶液、丝素蛋白水溶液和聚乙烯醇水溶液及葡萄糖流动过程中经过多次的分流混合,能够大大提高其混合效率及效果,混合过程中不需要停顿。As shown in FIGS. 1 and 7 , the mixing sleeve 12 further includes a plurality of
优选的,海藻酸钠水溶液质量分数为0.5%~2.0%、丝素蛋白水溶液质量分数为0.5%~2%、聚乙烯醇水溶液质量分数为0.5%~2%。Preferably, the mass fraction of the sodium alginate aqueous solution is 0.5%-2.0%, the mass fraction of the silk fibroin aqueous solution is 0.5%-2%, and the mass fraction of the polyvinyl alcohol aqueous solution is 0.5%-2%.
如图2、4所示,所述第一分流组件128包括第一锥形板145、设于第一锥形板内的第一腔体146、等距环形分布设于第一锥形板上的多个第一出水管147、贯穿设于第一锥形板上的多个第二出水管148、固定设于第二管体内壁上的第一固定环149、等距环形分布固定设于第一固定环上的多个分流板150、设于分流板中间处的第一通孔151;海藻酸钠水溶液通过多个第一弧形孔进入第一锥形板内的第一腔体,通过第一腔体上的多个第一出水管排出就进入第二管体和第三管体之间,第二管体和第三管体之间的丝素蛋白水溶液从多个第二出水管排出,通过第一锥形板设置使由内道外从第一出水管排出的海藻酸钠水溶液流速依次增加,使由内道外从第二出水管排出的丝素蛋白水溶液依次增加,在通过第一固定环设置从而使该处的二者混合后形成涡流,提高二者混合效果,再通过多个分流板使二者向其两侧流动,一部分通过其上的第一通孔流动,与经过相邻分流板分流的二者混合相碰触混合,第一出水管与第二出水管交错设置能够大大提高了二者的混合效果。As shown in FIGS. 2 and 4 , the
如图3、5、6所示,所述第三分流组件130包括设于第四管体轴心处的转轴152、固定套设于转轴上的第一轴套153、转动套设于转轴上且固定设于第四管体内壁上的第二轴套154、固定设于第四管体内壁上的第二固定环155、设于第二固定环中间处的第二通孔156、固定设于转轴上的旋涡状聚流板157、固定套设于转轴上的圆板158、等距设于旋涡状聚流板上的多个斜板159、位于斜板一端设于旋涡状聚流板上的第三通孔160、位于斜板另一端设于旋涡状聚流板上的第四通孔161;通过中和混合泵驱动转轴转动,使转轴上的旋涡状聚流板转动,第四管体内的葡萄糖从第四管体和圆板之间通过,与通过第三孔组进入的海藻酸钠水溶液、丝素蛋白水溶液和聚乙烯醇水溶液三者混合料,旋涡状聚流板转动过程中使四者混合料向其中间流动,从固定环中间处的第二通孔向第一轴套方向流动,使四者聚集混合,通过其上的多个斜板设置能够使四者改变其流动的方向,整体起到很好的混合效果,通过第三通孔和第四通孔能够减少旋涡状聚流板转动过程中受到的阻力,还能够使四者混合料流经第三通孔和第四通孔,提高其第三通孔和第四通孔处的流动速度,提高该处的混合效果,通过第一轴套和第二轴套设置能够使转轴转动过程中更为平稳,降低转动过程中的晃动,提高转轴的使用寿命,四者通过旋涡状聚流板聚集后从第二通孔向第一轴套方向流动,经过第一轴套再对四者进行分流,即先对四者进行聚流冲击混合,再对四者进行分流,大大提高了对四者的混合效果和效率。As shown in FIGS. 3 , 5 and 6 , the
如图3、9所示,所述第一轴套153包括套体162、固定设于套体一端的第一锥形体163、等距环形分布固定设于第一锥形体上的固定板164、转动设于固定板上的从动轴165、固定套设于从动轴上的第二锥形体166、固定套设于从动轴上的空心管167、等距环形分布设于空心管上的多个第五通孔168及第六通孔169、固定设于空心管一端的锥形环170;转轴转动过程中带动第一轴套转动,使套体转动,使第一锥形体转动,使第一锥形体上的多个固定板以转轴为轴心进行公转,通过第一锥形体设置能够使流经该处的四者混合料向外流动,流动过程中一部分直接进入空心管内,一部分通过第五通孔进入空心管内,使与直接进入空心管内的四者混合料相冲击混合,空心管内的混合料通过第六通孔排出,并流经第二锥形体,再次对其进行向外分流,通过从动轴转动设置在固定板上,从而使空心管可以转动,使位于其内的四者混合料更容易混合,空心管内的混合料一部分会从其它第五通孔流出,能够降低空心管公转过程中受到的阻力,通过空心管公转能够使四组流经该处时混合的更为全面。As shown in Figures 3 and 9, the
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011604061.0A CN112691077B (en) | 2020-12-30 | 2020-12-30 | Processing method of glucose injection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011604061.0A CN112691077B (en) | 2020-12-30 | 2020-12-30 | Processing method of glucose injection |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112691077A CN112691077A (en) | 2021-04-23 |
CN112691077B true CN112691077B (en) | 2022-04-05 |
Family
ID=75512269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011604061.0A Active CN112691077B (en) | 2020-12-30 | 2020-12-30 | Processing method of glucose injection |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112691077B (en) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030176282A1 (en) * | 2002-03-13 | 2003-09-18 | Appleton Papers Inc. | Uniform microcapsules |
CN2614212Y (en) * | 2003-03-08 | 2004-05-05 | 浙江大学医学院附属第二医院 | Multi channel microcapsule generating apparatus |
CN1572365A (en) * | 2003-05-30 | 2005-02-02 | 富士胶片株式会社 | Microdevice |
CN1867394A (en) * | 2003-10-16 | 2006-11-22 | 巴塞尔聚烯烃意大利有限责任公司 | Process for the continuous production of emulsions |
CN101909730A (en) * | 2008-01-10 | 2010-12-08 | 株式会社盛长 | Static fluid mixer |
CN102186570A (en) * | 2008-10-20 | 2011-09-14 | 旭有机材工业株式会社 | Helical fluid mixer and device using helical fluid mixer |
CN102753257A (en) * | 2010-02-05 | 2012-10-24 | 旭有机材工业株式会社 | Fluid-mixing apparatus and device using the same |
CN103002878A (en) * | 2010-04-09 | 2013-03-27 | 帕西拉制药有限公司 | Method for formulating large diameter synthetic membrane vesicles |
CN206240342U (en) * | 2016-07-07 | 2017-06-13 | 苏秋月 | A kind of biological medicine stainless steel |
CN107693488A (en) * | 2017-11-02 | 2018-02-16 | 重庆理工大学 | A kind of fat-soluble medicine sub-micro capsule glucose injection and preparation method thereof |
CN108043295A (en) * | 2017-12-07 | 2018-05-18 | 张荷友 | A kind of liquid food detection oscillating uniform device |
-
2020
- 2020-12-30 CN CN202011604061.0A patent/CN112691077B/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030176282A1 (en) * | 2002-03-13 | 2003-09-18 | Appleton Papers Inc. | Uniform microcapsules |
CN2614212Y (en) * | 2003-03-08 | 2004-05-05 | 浙江大学医学院附属第二医院 | Multi channel microcapsule generating apparatus |
CN1572365A (en) * | 2003-05-30 | 2005-02-02 | 富士胶片株式会社 | Microdevice |
CN1867394A (en) * | 2003-10-16 | 2006-11-22 | 巴塞尔聚烯烃意大利有限责任公司 | Process for the continuous production of emulsions |
CN101909730A (en) * | 2008-01-10 | 2010-12-08 | 株式会社盛长 | Static fluid mixer |
CN102186570A (en) * | 2008-10-20 | 2011-09-14 | 旭有机材工业株式会社 | Helical fluid mixer and device using helical fluid mixer |
CN102753257A (en) * | 2010-02-05 | 2012-10-24 | 旭有机材工业株式会社 | Fluid-mixing apparatus and device using the same |
CN103002878A (en) * | 2010-04-09 | 2013-03-27 | 帕西拉制药有限公司 | Method for formulating large diameter synthetic membrane vesicles |
CN206240342U (en) * | 2016-07-07 | 2017-06-13 | 苏秋月 | A kind of biological medicine stainless steel |
CN107693488A (en) * | 2017-11-02 | 2018-02-16 | 重庆理工大学 | A kind of fat-soluble medicine sub-micro capsule glucose injection and preparation method thereof |
CN108043295A (en) * | 2017-12-07 | 2018-05-18 | 张荷友 | A kind of liquid food detection oscillating uniform device |
Also Published As
Publication number | Publication date |
---|---|
CN112691077A (en) | 2021-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3574911B1 (en) | Bitter ganoderma lucidum spore powder and preparation method thereof | |
CN105944109A (en) | Glomerulus-targeted protein nanoparticle pharmaceutical composition and application thereof | |
WO2023165149A1 (en) | "immune exosome" nanoparticle loaded with traditional chinese medicine self-assembled micelles, preparation method therefor and application thereof | |
CN112691077B (en) | Processing method of glucose injection | |
CA2920533A1 (en) | Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof | |
CN107661724A (en) | A kind of medicament allotment mixing arrangement of conveniently moving | |
JP6505250B2 (en) | Filingening rucuronic acid derivative, method for preparing the same and application thereof | |
CN114376986B (en) | Bionic nanoparticle for homologous recombination exosome multi-drug delivery and preparation method and application thereof | |
CN104363950B (en) | Infusion catheter end for biological agent | |
CN104950067B (en) | A kind of TLC Identification of plate green grass or young crops superfine powder | |
CN109431905A (en) | A kind of Radix Arnebiae extract and its preparation method and application | |
WO2017129054A1 (en) | Medicament for treating uremia and proteinuria | |
CN1562195A (en) | Mediciation for curing chronic kidney function failure and its prepn. method | |
CN209227003U (en) | A kind of apyrogeneity gene therapy super spirial plasmid small size high power concentration filter wash device | |
CN108771660B (en) | Ciprofloxacin hydrochloride dry powder inhaler and preparation method thereof | |
CN106955331B (en) | A kind of pharmaceutical composition for treating chronic renal failure | |
CN106974917B (en) | Application of exodermis poria triterpene in preparation of medicine for treating nephropathy | |
CN114053305A (en) | Application of cell-free fat extract in treating lung diseases | |
CN117898943B (en) | Special preparation device suitable for preparation process of body pain and stasis removing emplastrum | |
CN115607508B (en) | Nasal administration preparation for preventing and treating pneumonia caused by influenza A virus and preparation method and application thereof | |
CN119499264A (en) | Astragaloside IV-salvianolic acid B-peonidin-amygdalin nanoliposome and preparation method thereof | |
CN116440188B (en) | Medical application of wrinkled giant hyssop leaf extract | |
CN113521008A (en) | A kind of preparation method of astragaloside IV nano-liposome | |
CN103110677B (en) | Preparation method of American ginseng extract, and application thereof in preparation of drug for preventing and treating acquired immunodeficiency syndrome | |
CN104784152A (en) | Thiamphenicol microcapsule, and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A processing method for glucose injection Effective date of registration: 20231019 Granted publication date: 20220405 Pledgee: ZHEJIANG DONGYANG RURAL COMMERCIAL BANK Co.,Ltd. Pledgor: Zhejiang Kancheer Pharmaceutical Co.,Ltd. Registration number: Y2023980061785 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20220405 Pledgee: ZHEJIANG DONGYANG RURAL COMMERCIAL BANK Co.,Ltd. Pledgor: Zhejiang Kancheer Pharmaceutical Co.,Ltd. Registration number: Y2023980061785 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A processing method for glucose injection solution Granted publication date: 20220405 Pledgee: ZHEJIANG DONGYANG RURAL COMMERCIAL BANK Co.,Ltd. Pledgor: Zhejiang Kancheer Pharmaceutical Co.,Ltd. Registration number: Y2024980049237 |